quantisnow
FeedTopReportsPricing
⌘K
Live feed
12:09:42·3d
ANALYSTRating
Agios Pharmaceuticals Inc. logo

H.C. Wainwright reiterated coverage on Agios Pharma with a new price target

AGIO· Agios Pharmaceuticals Inc.
Health Care
Original source

Companies

  • AGIO
    Agios Pharmaceuticals Inc.
    Health Care

Recent analyst ratings

  • Apr 20UpdateH.C. Wainwright$50.00
  • Nov 24UpdateTruist-
  • Nov 20UpdateLeerink Partners$34.00
  • Nov 19UpdateRBC Capital Mkts$28.00
  • Feb 24UpdateH.C. Wainwright$58.00
  • Oct 16UpdateScotiabank-

Related

  • INSIDER17d
    SEC Form 4 filed by Burns James William
  • INSIDER17d
    SEC Form 4 filed by Gheuens Sarah
  • INSIDER17d
    SEC Form 4 filed by Jones Cecilia
  • INSIDER17d
    SEC Form 4 filed by Milanova Tsveta
  • INSIDER17d
    SEC Form 4 filed by Viswanadhan Krishnan
  • INSIDER17d
    SEC Form 4 filed by Goff Brian
  • PR17d
    Agios to Host First Quarter 2026 Financial Results Conference Call and Webcast on April 29 at 8:00 a.m. ET
  • PR23d
    Agios Advances Mitapivat Toward Potential U.S. Accelerated Approval in Sickle Cell Disease Following Pre-sNDA Meeting with FDA
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022